n">(Reuters) - Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial.
Shares of the specialty pharmaceutical company rose 10.5 percent before the bell.
The study was testing the drug, BIOD-531, against Eli Lilly and Co's Humalog Mix 75/25 in type 2 diabetes patients with moderate insulin resistance who use 50-200 units of insulin daily.
In type 2 diabetes, the most common form of the disease, the body does not use insulin properly, leading to high levels of blood sugar.
Basal insulin, or long-acting insulin therapies, are usually prescribed to keep blood sugar levels in control between meals. Prandial insulin, or short-acting insulin therapies, are administered before meals to manage mealtime glucose.
Type 2 diabetes patients are usually given both basal and prandial insulin in a single injection such as Humalog Mix 75/25, Biodel said.
Humulin R U-500 is the only concentrated insulin available in the United States, the company said.
The therapy is used to treat type 2 diabetes patients with severe insulin resistance, who need greater than 200 units of insulin daily.
Danbury, Connecticut-based Biodel's shares closed at $1.91 on the Nasdaq on Friday.
(Reporting by Natalie Grover in Bangalore; Editing by Kirti Pandey)
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video
This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.